Table 1 Characteristics of patients at baseline (N = 88 patients)
From: Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients
Characteristics | Mean or percentage |
|---|---|
Age (year), mean (SD) | 64 (14) |
Sex (male), n (%) | 38 (43.2) |
IV dosage of alfacalcidol, mean (SD) | 2.1 μg 3 times a week (0.86) |
ESRD etiology, n (%) | |
Diabetic nephropathy | 30 (34) |
Hypertensive nephropathy | 30 (34) |
Glomerular disease | 15 (17) |
Others | 13 (15) |
Cinacalcet use, n (%) | 30 (34) |
Phosphate binders use, n (%) | |
Calcium based | 64 (72) |
Sevelamer | 50 (57) |
Lanthanum | 9 (10) |
No phosphate binder | 8 (9) |
25 vitamin D use, n (%) | 0 (0) |